@article {Afaq89, author = {Asim Afaq and Suliman Alahmed and Shih-hsin Chen and Thabo Lengana and Athar Haroon and Heather Payne and Hashim Ahmed and Shonit Punwani and Mike Sathekge and Jamshed Bomanji}, title = {Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management}, volume = {59}, number = {1}, pages = {89--92}, year = {2018}, doi = {10.2967/jnumed.117.192625}, publisher = {Society of Nuclear Medicine}, abstract = {The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39\%). The management changes occurred in 23 (33.8\%) of 68 patients with radical prostatectomy and 16 (50\%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P \< 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39\% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/59/1/89}, eprint = {https://jnm.snmjournals.org/content/59/1/89.full.pdf}, journal = {Journal of Nuclear Medicine} }